EP2022849A4 - Procédé permettant une prolifération du virus de la grippe - Google Patents

Procédé permettant une prolifération du virus de la grippe

Info

Publication number
EP2022849A4
EP2022849A4 EP07743165A EP07743165A EP2022849A4 EP 2022849 A4 EP2022849 A4 EP 2022849A4 EP 07743165 A EP07743165 A EP 07743165A EP 07743165 A EP07743165 A EP 07743165A EP 2022849 A4 EP2022849 A4 EP 2022849A4
Authority
EP
European Patent Office
Prior art keywords
proliferation
influenza virus
influenza
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07743165A
Other languages
German (de)
English (en)
Other versions
EP2022849A1 (fr
Inventor
Toshinobu Nouchi
Kiyoto Nishiyama
Keishin Sugawara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Publication of EP2022849A1 publication Critical patent/EP2022849A1/fr
Publication of EP2022849A4 publication Critical patent/EP2022849A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP07743165A 2006-05-11 2007-05-11 Procédé permettant une prolifération du virus de la grippe Withdrawn EP2022849A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006132049 2006-05-11
PCT/JP2007/059730 WO2007132763A1 (fr) 2006-05-11 2007-05-11 Procédé permettant une prolifération du virus de la grippe

Publications (2)

Publication Number Publication Date
EP2022849A1 EP2022849A1 (fr) 2009-02-11
EP2022849A4 true EP2022849A4 (fr) 2010-10-06

Family

ID=38693857

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07743165A Withdrawn EP2022849A4 (fr) 2006-05-11 2007-05-11 Procédé permettant une prolifération du virus de la grippe

Country Status (4)

Country Link
US (1) US7883844B2 (fr)
EP (1) EP2022849A4 (fr)
JP (1) JP5322636B2 (fr)
WO (1) WO2007132763A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
AR080972A1 (es) 2010-04-28 2012-05-23 Abbott Biologicals Bv Produccion de componentes virales
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (fr) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Réplication améliorée du virus de la grippe pour l'élaboration de vaccin
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
WO2019084310A1 (fr) 2017-10-25 2019-05-02 Yoshihiro Kawaoka Virus de la grippe recombinants à ha stabilisé pour la réplication dans des oeufs
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
EP3914295A2 (fr) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations conférant une stabilité génétique à des gènes supplémentaires dans des virus de la grippe
WO2020163804A1 (fr) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Lignée cellulaire humanisée
AU2020222577B2 (en) 2019-02-14 2024-08-08 Kao Corporation Proliferation method
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
WO2021041624A2 (fr) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Virus de la grippe recombinants à ha stabilisé pour réplication dans des oeufs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
JP2021136899A (ja) * 2020-03-04 2021-09-16 花王株式会社 ウイルス増殖方法及びウイルス増殖促進剤の探索方法
WO2021195410A1 (fr) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Virus de la grippe multivalents recombinants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
WO1997037000A1 (fr) * 1996-04-01 1997-10-09 Chiron Behring Gmbh & Co. Cellules animales et procedes de replication des virus de la grippe

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1122527A (fr) 1979-05-15 1982-04-27 Karen K. Brown Production d'un vaccin contre l'influenza par culture de cellules en milieu liquide
JPS62201574A (ja) 1986-02-27 1987-09-05 Shionogi & Co Ltd 家禽用インフルエンザワクチン
AU694592B2 (en) 1994-11-16 1998-07-23 St. Jude Children's Research Hospital Novel replication process
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
CA2401117C (fr) * 2000-03-03 2010-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule
IT1319453B1 (it) * 2000-06-09 2003-10-10 Dario Felisario Dispositivo elettrotermico per l'accesione e la rilevazione di fiammain bruciatori a gas.
WO2005026333A1 (fr) * 2003-09-09 2005-03-24 Japan Science And Technology Agency Technique de culture en suspension de cellules adherentes a l'aide de proteases et methode de production d'un virus utilisant les cellules comme hotes
JP2005184500A (ja) 2003-12-19 2005-07-07 Nec Corp 障害監視システム、障害監視方法、監視装置及びそのプログラム
JP4115437B2 (ja) 2004-08-30 2008-07-09 株式会社ソフィア 遊技機の球貯留皿
WO2006051946A1 (fr) 2004-11-15 2006-05-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Nouveau polypeptide ayant une activité d'inhibition des protéases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
WO1997037000A1 (fr) * 1996-04-01 1997-10-09 Chiron Behring Gmbh & Co. Cellules animales et procedes de replication des virus de la grippe
US6656720B2 (en) * 1996-04-01 2003-12-02 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
KESSLER N ET AL: "SUITABILITY OF MDCK CELLS GROWN IN A SERUM-FREE MEDIUM FOR INFLUENZA VIRUS PRODUCTION", DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, KARGER, BASEL, CH, vol. 98, 1 January 1999 (1999-01-01), pages 13 - 21,73/74, XP001097586 *
MANCINI D A P ET AL: "AVALIACAO DA TRIPSINA NA MULTIPLICACAO DE VIRUS INFLUENZA EM CULTURAS DE CELULAS MDCK", REVISTA DE FARMACIA E BIOQUIMICA DA UNIVERSIDADE DE SAO PAULO, SAO PAULO, BR, vol. 29, no. 2, 1 July 1993 (1993-07-01), pages 89 - 95, XP002039318, ISSN: 0370-4726 *
MERTEN O W ET AL: "PRODUCTION OF INFLUENZA VIRUS IN CELL CULTURES FOR VACCINE PREPARATION", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRINGER, US, vol. 397, 1 January 1996 (1996-01-01), pages 141 - 151, XP000982880, ISSN: 0065-2598 *
MERTEN O-W ET AL: "PRODUCTION OF INFLUENZA VIRUS IN SERUM-FREE MAMMALIAN CELL CULTURES", DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, KARGER, BASEL, CH, vol. 98, 1 January 1997 (1997-01-01), pages 23 - 37, XP000909398 *
MERTEN O-W ET AL: "THE NEW MEDIUM MDSS2N, FREE OF ANY ANIMAL PROTEIN SUPPORTS CELL GROWTH AND PRODUCTION OF VARIOUS VIRUSES", CYTOTECHNOLOGY, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL LNKD- DOI:10.1023/A:1008021317639, vol. 30, no. 1-3, 1 January 1999 (1999-01-01), pages 191 - 201, XP000978974, ISSN: 0920-9069 *
Product Information EX-CELL 293 Serum-Free Medium for HEK 293 Cells SAFC Bioseciences Catalog No. 14571C September 2006 *
See also references of WO2007132763A1 *

Also Published As

Publication number Publication date
US20090181446A1 (en) 2009-07-16
EP2022849A1 (fr) 2009-02-11
JPWO2007132763A1 (ja) 2009-09-24
WO2007132763A1 (fr) 2007-11-22
US7883844B2 (en) 2011-02-08
JP5322636B2 (ja) 2013-10-23

Similar Documents

Publication Publication Date Title
EP2325648A4 (fr) Procédé de détection du cancer
EP2063270A4 (fr) Procédé de diagnostic rapide spécifique du virus de la grippe aviaire
EP2024509A4 (fr) Procédé de détection
EP2445349A4 (fr) Composés et procédés pour traiter la grippe
EP2106410A4 (fr) Procédé de sulfonation de polymères séquencés
EP2070636A4 (fr) Procédé de traitement laser
EP2070635A4 (fr) Procédé de traitement laser
BRPI0820689A2 (pt) processo de produção de um derivado de indolinona
DK1981863T3 (da) Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater
EP2137280A4 (fr) Procédé de traitement de formation fracturée
EP2128265A4 (fr) Procédé de glycosylation de flavonoïde
EP2327488A4 (fr) Procédé de cisaillement de tôle
EP2515107A4 (fr) Procédé de quantification de caroténoïde
EP2278755A4 (fr) Procédé de traitement de paquets
EP2152945A4 (fr) Procédé de décortication
EP2376923A4 (fr) Procédé de détection de sepsie
EP2028937A4 (fr) Traitement par un agoniste de la mélatonine
EP2350641A4 (fr) Procédé de traitement
EP2132570A4 (fr) Procédé de criblage
EP2396281A4 (fr) Procédé de désioduration
EP2044225A4 (fr) Procédé de séparation
EP2455751A4 (fr) Procédé de quantification de protéine
EP2308819A4 (fr) Procédé de synthèse de sévoflurane
EP2446250A4 (fr) Procédé de détection de contaminants
EP2267764A4 (fr) Procédé de traitement par plasma

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20100908

17Q First examination report despatched

Effective date: 20120220

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 7/00 20060101AFI20160627BHEP

INTG Intention to grant announced

Effective date: 20160718

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161129